07.02.26 -- EMA's New Guideline For Synthetic Peptides: A More Explicit CMC Playbook For A Growing Therapeutic Class

Platform biotech companies face critical choices on partnering, licensing, or selling technology—decisions that shape focus, valuation, and long‑term success beyond scientific innovation alone.

Paper-based records still shape many life sciences operations, but they bring hidden risks. Gain insight into how manual documentation impacts accuracy, efficiency, and compliance.

Watch as Quentin Horgan, Director of Drugs Intelligence at GlobalData discusses how early-stage insights can improve development outcomes and reduce downstream risk.

Maximize the oral bioavailability of challenging small-molecule candidates and streamline the path from preclinical toxicology to clinical trials by leveraging optimized lipid-based formulations.

The session focuses on the use of T3P (propanephosphonic acid anhydride) in amidation and peptide coupling reactions, including both liquid-phase and solid-phase peptide synthesis.

Small-scale downstream studies play a critical role in enabling efficient, low-risk tech transfer for biologics development.

Maintaining cGMP standards, controlling particulate contamination ensures drug safety, quality, effectiveness, and shelf life while preventing immune reactions and regulatory noncompliance.

Automated manufacturing is a powerful but often misunderstood tool available to produce drug delivery and other pharmaceutical devices — whether established designs or innovative new ideas.

Overcome solubility challenges and utilize flexible development strategies to transition innovative treatments from early-phase trials to commercialization while ensuring patient safety.